Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F de Groot

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Neuro-Oncology|December 7, 2013
Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiationChristian L Barney, Aaron P Brown, David R Grosshans, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2019
Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer CenterRebecca A Harrison, Mark D Anderson, David Cachia, et al.
Oncotarget|March 15, 2018
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cellsJianwen Dong, Soon Young Park, Nghi Nguyen, et al.
Journal of Neuro-Oncology|August 31, 2012
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiformeKenneth F Grossmann, Howard Colman, Wallace A Akerley, et al.
International Journal of Radiation Oncology, Biology, Physics|February 26, 2013
Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastomaAaron P Brown, Christian L Barney, David R Grosshans, et al.
Neuro-Oncology|December 18, 2019
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)Timothy F Cloughesy, Andrew Brenner, John F de Groot, et al.
Journal of Neuro-Oncology|September 13, 2018
The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective studyXiaojie Ding, Zheng Wang, Di Chen, et al.
Neuro-Oncology|February 11, 2004
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposiumRamsis K Benjamin, Fred H Hochberg, Elizabeth Fox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in GlioblastomaShaofang Wu, Feng Gao, Siyuan Zheng, et al.
Journal of Neuro-Oncology|July 14, 2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaShiao-Pei Weathers, Xiaosi Han, Diane D Liu, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Neuro-Oncology|December 7, 2013
Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiationChristian L Barney, Aaron P Brown, David R Grosshans, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2019
Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer CenterRebecca A Harrison, Mark D Anderson, David Cachia, et al.
Oncotarget|March 15, 2018
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cellsJianwen Dong, Soon Young Park, Nghi Nguyen, et al.
Journal of Neuro-Oncology|August 31, 2012
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiformeKenneth F Grossmann, Howard Colman, Wallace A Akerley, et al.
International Journal of Radiation Oncology, Biology, Physics|February 26, 2013
Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastomaAaron P Brown, Christian L Barney, David R Grosshans, et al.
Neuro-Oncology|December 18, 2019
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)Timothy F Cloughesy, Andrew Brenner, John F de Groot, et al.
Journal of Neuro-Oncology|September 13, 2018
The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective studyXiaojie Ding, Zheng Wang, Di Chen, et al.
Neuro-Oncology|February 11, 2004
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposiumRamsis K Benjamin, Fred H Hochberg, Elizabeth Fox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in GlioblastomaShaofang Wu, Feng Gao, Siyuan Zheng, et al.
Journal of Neuro-Oncology|July 14, 2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaShiao-Pei Weathers, Xiaosi Han, Diane D Liu, et al.
Pageof 13